RMT-Epigenomex, Inc.
Reducing Time & Cost for Drug Discovery



RMT's patented arginine-based screening method is branded under the name ARGeneticsTM.  Our technology is highly scalable and focused on the discovery and pre-clinical stages.  

Services


The ARGeneticsTM service platform provides customers (Pharma & Biotech Companies; larger CROs) with testing information on experimental new drugs, classified as “new molecular entities” (NME) or “new chemical entities” (NCE) or other members of a chemical library under consideration for future development as an “investigational new drug”.

 

The results of the testing, returned to the customer in the form of a report, allows NME and NCE programs to evaluate:

(a) the top candidates for further development, including IND status

(b) the rank ordering of the potential in vitro effectiveness of individual chemical compounds derived from a chemical library of experimental chemical agents

(c) the rank ordering of the potential effectiveness and toxicity of individual chemical compounds derived from a chemical library of experimental chemical agents in cultured cells

(d) the potential protein drug targets of new chemical agents derived from a chemical library

(e) the identification and validation of biomarkers that may be informative about the effectiveness of the NME/NCE program


Core Service Offerings Include:

Screening ARGeneticsTM: generation of a primary drug "hit list" 

Biomarker ARGeneticsTM: methyl-biomarker identification/validation 

Target ARGeneticsTM: difference analysis (disease vs. normal) for rapid assembly of lists of potential 
   drug targets 

Discover ARGeneticsTM: hit to lead and lead optimization studies 

Culture ARGeneticsTM: early stage in vivo analysis of drug action and toxicity in cultured cells



PRODUCTS



CH3 BioSystemsTM: supplier of high-performance molecular tools and services. Click here for more information